CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production.

ABSTRACT: Chimeric antigen receptor (CAR)-T cells are engineered to identify and eliminate cells expressing a target antigen. Current manufacturing protocols vary between commercial CAR-T cell products warranting an assessment of these methods to determine which approach optimally balances successful manufacturing capacity and product efficacy. One difference between commercial product manufacturing methods is whether T cell engineering begins with fresh (unfrozen) patient cells or cells that have been cryopreserved prior to manufacture. Starting with frozen PBMC material allows for greater manufacturing flexibility, and the possibility of collecting and storing blood from patients prior to multiple lines of therapy. We prospectively analyzed if second generation anti-CD19 CAR-T cells with either CD

SUBMITTER: Abraham-Miranda J 

PROVIDER: S-EPMC9549966 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature